Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Infectious Diseases

• Publication date

  2005-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/498149PMID 16288390
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CAPNETZ—Community-Acquired Pneumonia Competence Network

  2004cited by this paper
• Prognostic scoring systems for infectious diseases: their applicability to the care of older adults.

  2004cited by this paper
• Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers.

  2003cited by this paper
• Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials.

  2003cited by this paper
• Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia

  2003cited by this paper
• High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.

  2003cited by this paper
• Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults

  2003cited by this paper
• Erratum: High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm (Clinical Infectious Diseases (2003) 37 (752-60))

  2003cited by this paper
• Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment

  2002cited by this paper
• Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

  2001cited by this paper
• Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial.

  2001cited by this paper
• ANTIBIOTHERAPIE PAR VOIE GENERALE EN PRATIQUE COURANTE

  2001cited by this paper
• Moxifloxacin in Acute Exacerbations of Chronic Bronchitis: Clinical Evaluation and Assessment by Patients

  2001cited by this paper
• Treatment Outcomes in Acute Exacerbations of Chronic Bronchitis: Comparison of Macrolides and Moxifloxacin from the Patient Perspective

  2001cited by this paper
• A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.

  2000cited by this paper
• Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults

  2000cited by this paper
• Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.

  1999cited by this paper
• The cost of treating community-acquired pneumonia.

  1998cited by this paper
• ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society.

  1998cited by this paper
• Guidelines for the initial Management of Adults with Community-acquired Pneumoma : Diagnosis , Assessment of Severity ; and initial Antimicrobial fieraky

  1998cited by this paper
• Guidelines for management of adult community-acquired lower respiratory tract infections

  1998cited by this paper
• A prediction rule to identify low-risk patients with community-acquired pneumonia.

  1997cited by this paper
• Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association.

  1993cited by this paper

• Empiric antibiotic therapy for moderate to severe community-acquired pneumonia: a systematic review and network meta-analysis.

  2025cites this paper
• A Review on the Role of Moxifloxacin in the Treatment and Management of Respiratory Tract Infections

  2025cites this paper
• Respiratory fluoroquinolone monotherapy versus β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomised controlled trials.

  2023cites this paper
• Empirical Antibiotic Treatment Strategies for Community-Acquired Pneumonia: A Network Meta-analysis.

  2022cites this paper
• Comparing Several Treatments with Antibiotics for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2021influential citation
• Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin hydrochloride.

  2020cites this paper
• Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain

  2019cites this paper
• Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis

  2019cites this paper
• Beneficial effects of early empirical administration of appropriate antimicrobials on survival and defervescence in adults with community-onset bacteremia

  2019cites this paper
• Beta-lactam plus a Macrolide versus a Fluoroquinolone for Empiric Therapy of Hospitalized Patients with Community-Acquired Pneumonia: Results from the University of Louisville Pneumonia Study

  2019cites this paper
• Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis

  2019cites this paper
• Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community‐acquired pneumonia: A meta‐analysis

  2018cites this paper
• Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review

  2018cites this paper
• The dilemma of monotherapy or combination therapy in community‐acquired pneumonia

  2017cites this paper
• Has Mortality of Community-Acquired Pneumonia Really Reduced?

  2017cites this paper
• Addressing current challenges in antibiotic treatment of community acquired pneumonia

  2017cites this paper
• Declining mortality among hospitalized patients with community-acquired pneumonia.

  2016cites this paper
• Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection

  2016cites this paper
• Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy

  2016cites this paper
• [Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia].

  2015cites this paper
• The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia

  2015cites this paper
• What Is New in Antibiotic Therapy in Community-Acquired Pneumonia? An Evidence-Based Approach Focusing on Combined Therapy

  2015cites this paper
• Moxifloxacin Pharmacokinetic Profile and Efficacy Evaluation in Empiric Treatment of Community-Acquired Pneumonia

  2015cites this paper
• Comparative Treatment Failure Rates of Respiratory Fluoroquinolones or β-Lactam + Macrolide Versus β-Lactam Alone in the Treatment for Community-Acquired Pneumonia in Adult Outpatients

  2015cites this paper
• Time to reconsider how we do antibiotic therapy trials.

  2015cites this paper
• Managing CAP patients at risk of clinical failure.

  2015cites this paper
• Participation of Elderly Adults in Randomized Controlled Trials Addressing Antibiotic Treatment of Pneumonia

  2015cites this paper
• Gender Analysis of Moxifloxacin Clinical Trials

  2014cites this paper
• Assessment of bias in outcomes reported in trials on pneumonia: a systematic review

  2014cites this paper
• Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)

  2014cites this paper
• Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?

  2013cites this paper
• Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.

  2013cites this paper
• New treatments for emerging cystic fibrosis pathogens other than Pseudomonas.

  2012cites this paper
• Update on the Cardiac Safety of Moxifloxacin

  2012cites this paper
• Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.

  2012cites this paper
• Comparing therapeutic and adverse effects of moxifloxacin and levofloxacin in treatment of community acquired pneumonia: A meta-analysis of randomized controlled trials

  2012cites this paper
• Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials

  2012cites this paper
• Are Fluoroquinolones Superior Antibiotics for the Treatment of Community-Acquired Pneumonia?

  2012cites this paper
• Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

  2012cites this paper
• Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.

  2011cites this paper
• Pleural Fluid Analysis in Chylothorax

  2011cites this paper
• Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis

  2011cites this paper
• Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.

  2011cites this paper
• Klinické doporu čení: Diagnostika a lé čba komunitní pneumonie

  2011cites this paper
• Comparision of Efficacy and Safety of Moxifloxacin Monotherapy Versus Ceftriaxone Plus Clarithromycin in Hospitalized Adult Community-Acquired Pneumonia (CAP) Patients With Risk Factors

  2011cites this paper
• Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.

  2010cites this paper
• Fluoroquinolones in the management of community-acquired pneumonia in primary care

  2010cites this paper
• Fluoroquinolones in the management of community‐acquired pneumonia

  2010cites this paper
• Clinical Efficacy of Moxifloxacin Versus Comparator Therapies for Community-Acquired Pneumonia Caused by Legionella spp.

  2010cites this paper
• Ambulant erworbene Pneumonie

  2009cites this paper
• New insights into pneumococcal disease

  2009cites this paper
• Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.

  2009cites this paper
• BTS guidelines for the management of community acquired pneumonia in adults: update 2009

  2009cites this paper
• 10 years’ experience with the pneumococcal quinolone moxifloxacin

  2009cites this paper
• Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen unteren Atemwegsinfektionen sowie ambulant erworbener Pneumonie – Update 2009

  2009cites this paper
• Early and Late Treatment Failure in Community-Acquired Pneumonia

  2009cites this paper
• [Community-acquired pneumonia].

  2009cites this paper
• British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009

  2009cites this paper
• Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia

  2008cites this paper
• Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

  2008cites this paper
• Moxifloxacin: update and perspectives after 8 years of usage

  2008cites this paper
• Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment

  2008cites this paper
• What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.

  2008cites this paper
• Community-Acquired Pneumonia—Back to Basics

  2008cites this paper
• Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.

  2008cites this paper
• Pneumococcal Pneumonia in Adults: Epidemiology, Clinical Features, Diagnosis, and Therapy

  2008cites this paper
• The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.

  2008cites this paper
• Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials

  2008cites this paper
• A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial

  2008cites this paper
• Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

  2008cites this paper
• Moxifloxacin: a respiratory fluoroquinolone

  2008cites this paper
• XVe Conférence de consensus en thérapeutique anti-infectieuse

  2007cites this paper
• A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)

  2007cites this paper
• [Treatment of community acquired pneumonia].

  2007cites this paper
• A Randomized Study of Sequential Intravenous/Oral Moxifloxacin in Comparison to Sequential Intravenous Ceftriaxone/Oral Cefuroxime Axetil in Patients with Hospital-Acquired Pneumonia

  2007cites this paper
• Diagnosis and treatment of community acquired pneumonia - the German perspective

  2007cites this paper
• brief review of moxi fl oxacin in the treatment of elderly patients with community-acquired pneumonia ( CAP )

  2007cites this paper
• Die ambulant erworbene Pneumonie: Weiterhin eine gefährliche Krankheit? - Neue S3-Leitlinie orientiert sich an Risiko- und Schweregrad

  2007cites this paper
• Quel antibiotique pour une pneumonie aiguë communautaire de l'adulte ?

  2006cites this paper
• [Acute community-acquired pneumonia. A review of clinical trials].

  2006cites this paper
• Treatment with moxifloxacin versus standard therapy for community-acquired pneumonia.

  2006cites this paper
• Pneumonie – erregerbasierte oder konstellationsbasierte Therapie?

  2006cites this paper
• Optimizing therapy for community-acquired pneumonia with the goal of rapid resolution of illness.

  2006cites this paper
• Was gibt es Neues in der Behandlung der ambulant erworbenen Pneumonie?

  2006cites this paper
• [Pneumonia - pathogen-based or constellation-based therapy?].

  2006cites this paper
• [Antibiotherapy for acute CAP in adults].

  2006cites this paper
• Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?

  2006cites this paper
• Monotherapy versus Combination Therapy in Patients Hospitalized with Community-Acquired Pneumonia

  2006cites this paper
• Pharmacoeconomics of treatment with the newer anti-Gram-positive agents

  2006cites this paper
• Do fluoroquinolones actually increase mortality in community-acquired pneumonia?

  2006influential citation
• Controversies in the treatment of pneumococcal community-acquired pneumonia.

  2006cites this paper
• Pneumonies aiguës communautaires : analyse critique des essais cliniques

  2006cites this paper
• Treatment of hospitalized patients with community-acquired pneumonia.

  2006cites this paper
• Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.

  2006cites this paper
• Was gibt es Neues in der Behandlung der ambulant erworbenen Pneumonie?

  2005cites this paper
• [New therapeutic strategies for community acquired pneumonia].

  2005cites this paper
• Editorial Commentary: Optimizing Therapy for Community‐Acquired Pneumonia with the Goal of Rapid Resolution of Illness

  2005cites this paper
• International Journal of Copd Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Gemifloxacin Use in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis

  year unknowncites this paper